MBFT is developing innovative new products to treat cancer in dogs and cats.


Our lead product is MBFT-101, a targeted, broad-spectrum Polyamine-Based Therapy (PaBT™) combination of two small molecules: difluoromethylornithine (DFMO) and the polyamine transport inhibitor, MBF-1569. MBFT-101 has a unique, potent and targeted mode of action that attacks cancer cells directly and also elicits an immune response against the tumor.

Product: MBFT-101

How It Works

DFMO and MBFT-1569 act in two different ways to cause polyamine starvation in tumor cells: DFMO inactivates ornithine decarboxylase (ODC), the key enzyme that tightly regulates cellular polyamine metabolism in healthy cells but becomes unregulated in cancer, leading to uncontrolled cell growth.  MBFT-1569 blocks polyamine transport, preventing the influx of extracellular polyamines into tumor cells that would replace the polyamines lost by ODC inactivation.


These metabolically impaired tumor cells become vulnerable to attack by the immune system.


Tumors have evolved many mechanisms or ‘shields’ to evade recognition by the immune system.  MBFT-101 destroys this ‘shield’, enabling cytotoxic T cells to recognize, attack and destroy tumor cells while leaving healthy cells unaffected. 

A. The actively growing tumor is ‘shielded’ from the immune system.


B. Treatment with MBFT-101 shrinks tumor cells by polyamine starvation and destruction of the ‘shield’ that protects the tumor from immune recognition. This enables cytotoxic T cells to recognize and destroy tumor and metastatic cells. C. The targeted action of MBFT-101 destroys the tumor without affecting healthy cells, with long-term protection provided by a durable, systemic immune response.

MBFT is collaborating with Dr. Susan Gilmour, a leading expert on polyamines and cancer at the Lankenau Institute for Medical Research (LIMR) on research, development and clinical evaluation. 


An MBFT-101 clinical study in cats with non-resectable oral squamous cell carcinoma (SCC) was conducted at the University of Pennsylvania’s School of Veterinary Medicine. SCC is an aggressive cancer and the most common feline oral tumor. The prognosis is very poor because of the rapid growth and advanced disease stage at the time of diagnosis. The study demonstrated significantly increased survival time compared with historical controls. Good quality of life during the treatment period and high satisfaction was reported by the pet owners, who administered the oral formulation at home.


  • LinkedIn Classic
  • Facebook Classic
  • Twitter Social Icon

​Follow us at @mbftherapeutics

© 2020 MBF Therapeutics.   Advanced Immunotherapeutics for Life Sciences.  All rights reserved.